Wang Hai-Feng, Lv Jie-Qing
Gastrointestinal Tumor Surgery Department, Shaoxing People's Hospital, Zhejiang University, Shaoxing, 312000, Zhejiang, People's Republic of China.
Cell Biochem Biophys. 2015 Jul;72(3):695-9. doi: 10.1007/s12013-015-0520-0.
The aim of this study is to explore the clinical effect of tegafur gimeracil oteracil combined with pirarubicin hydrochloride (THP) and diamminedichloroplatinum (DDP) for second-line treatment of advanced cardiac carcinoma, and find the most effective method to improve its survival rate and decrease the adverse reactions. 70 patients with advanced cardiac carcinoma admitted during February 2010-March 2014 were selected and divided into two groups with 35 cases in each group. All patients were treated with THP and DDP, and tegafur gimeracil oteracil was added to the observation group. The differences of effective rate, life quality, and adverse reactions after treatment in observational group were observed. The result of total curative effect indicated that the occurrence rate of complete remission + partial remission (CR + PR) in the control group was 28.57 %, the total effective rate was 51.43 %, the occurrence rate of CR + PR in the observational group was 34.29 %, and the total effective rate was 57.15 %; there was no statistical difference between the two groups (P > 0.05). The result of KPS scoring indicated that the improvement rate in the control group was 28.57 %, the total effective rate was 62.86 %, the improvement rate in the observational group was 42.86 %, and the total effective rate was 80 %; there was statistical difference between two groups (P < 0.05); the occurrence rates of adverse reactions including leukocyte decrease, thrombocytopenia, anemia, nausea and vomiting, constipation, peripheral neurovirulence, hepatotoxicity, and renal toxicity were statistically different (P < 0.05). Tegafur gimeracil oteracil combined with THP and DDP in treating advanced cardiac carcinoma can improve the life quality and decrease the adverse reactions.
本研究旨在探讨替吉奥联合盐酸吡柔比星（THP）及顺铂（DDP）二线治疗晚期贲门癌的临床疗效，寻找提高其生存率及降低不良反应的最有效方法。选取2010年2月至2014年3月收治的70例晚期贲门癌患者，分为两组，每组35例。所有患者均采用THP及DDP治疗，观察组在此基础上加用替吉奥。观察两组治疗后有效率、生活质量及不良反应的差异。总疗效结果显示，对照组完全缓解+部分缓解（CR+PR）发生率为28.57%，总有效率为51.43%，观察组CR+PR发生率为34.29%，总有效率为57.15%；两组比较差异无统计学意义（P>0.05）。KPS评分结果显示，对照组改善率为28.57%，总有效率为62.86%，观察组改善率为42.86%，总有效率为80%；两组比较差异有统计学意义（P<0.05）；两组白细胞减少、血小板减少、贫血、恶心呕吐、便秘、外周神经毒性、肝毒性及肾毒性等不良反应发生率比较差异有统计学意义（P<0.05）。替吉奥联合THP及DDP治疗晚期贲门癌可提高生活质量并降低不良反应。
